Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04402918
Other study ID # 2020/500
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 17, 2020
Est. completion date August 2, 2021

Study information

Verified date July 2021
Source Centre Hospitalier Universitaire de Besancon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study evaluates the distribution of immunological and virological profiles of newborns patients. Mothers of these children have a proven infection to SARS Cov-2 during pregnancy.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date August 2, 2021
Est. primary completion date May 19, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - pregnant woman - diagnosed with Sars Cov-2 during pregnancy - singleton or twin pregnancy - informed consent Exclusion Criteria: - virological or serological samples not done the day of delivery

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
biological samples day of delivery
mother samples: serology, viremia, nasopharyngeal swab, vaginal swab, placenta swab, piece of placenta newborn: serology, viremia, nasopharyngeal aspiration

Locations

Country Name City State
France Chu Besancon Besancon

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Besancon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Vrological profile of newborns. Describe the virological profile of newborns whose mother have been diagnosed with Sars Cov2 during pregnancy : Covid+ or covid- day of delivery
Primary Immunological profile of newborns. Describe the immunological profile of newborns whose mother have been diagnosed with Sars Cov2 during pregnancy : IgG and/or IgM or absence day of delivery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04446065 - Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers Phase 2/Phase 3
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Not yet recruiting NCT04400019 - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Phase 2/Phase 3
Completed NCT04463004 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Phase 2
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2
Recruiting NCT04441372 - Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
Recruiting NCT04581148 - SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Completed NCT04530604 - Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS) Phase 1
Active, not recruiting NCT04635605 - Methylene Blue Treatment of COVID-19 Phase 2
Recruiting NCT04395599 - Risk of Air Contamination During Visceral Surgery in COVID19 Patients N/A
Recruiting NCT04472585 - Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients Phase 1/Phase 2
Active, not recruiting NCT04411433 - Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 Phase 3
Completed NCT04359706 - Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
Recruiting NCT04395794 - SARS-CoV-2 Disguise Study
Completed NCT04386551 - Detection of COVID-19 in Saliva Collection
Recruiting NCT04403269 - NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE Phase 2
Withdrawn NCT04379492 - A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 Phase 2
Completed NCT04379336 - BCG Vaccination for Healthcare Workers in COVID-19 Pandemic Phase 3